Dr. Ashley's primary research focus is laboratory based, investigating the role of immunotherapy as a novel approach to the treatment of tumors of the central nervous system (CNS). Since beginning his appointment at the faculty level at Duke in August of 1995 his activities have centered on two main areas of investigation. The first involves both in vivo and in vitro studies of the use of molecular therapeutics to target a CNS tumor associated antigen. The second area of interest comprises a detailed analysis of the role of TGF beta, a protein messenger produced by tumors of the CNS, both in the pathogenesis of disease and as a possible target for immunotherapy.
In addition to his laboratory role Dr. Ashley is involved in the design and application of a variety of clinical research protocols in the treatment of children with malignant brain tumors.
Education and Training
- Ph.D., University of Melbourne (Australia), 1998
- M.B.B.S., University of Melbourne (Australia), 1994
- F.R.A.C.P., Royal Australasian College of Physicians (Australia), 1993
- PNOC 019: A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
- 6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma" A Duke and UTSW Collaboration
- CONNECT 1903: Larotrectinib for Children with high-grade glioma with NTRK Fusion
- A Phase II study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours (ATRT)
- Duke Center for Advancement of Child Health (CAtCH).
- NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEMPRIMITIVE NEURO-ECTODERMAL TUMORS:CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WI
- Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma
- NINDS Research Education Programs for Residents and Fellows in Neurosurgery
- Identifying brainstem glioma subtypes that can be radiosensitized by ATM inhibition
- Experimental Therapy for Brain Tumors
- Enhancing the efficacy of radiation therapy for brainstem gliomas
- PRECLINICAL THERAPEUTIC SCREENING FOR NEW THERAPIES FOR GLIOBLASTOMA MULTIFORME